Literature DB >> 2241902

Expression of human liver arginase in Escherichia coli. Purification and properties of the product.

M Ikemoto1, M Tabata, T Miyake, T Kono, M Mori, M Totani, T Murachi.   

Abstract

Arginase is an enzyme that catalyses the hydrolysis of arginine to urea and ornithine. It is abundantly present in the liver of ureotelic animals (i.e. those whose excretion is characterized by the excretion of uric acid as the chief end-product of nitrogen metabolism), but its purification has hitherto not been simple, and the yield not high. Starting with a partially truncated cDNA for human liver arginase recently made available, we constructed an expression plasmid that had tandemly linked tac promotors placed upstream of a full-length cDNA. By selecting Escherichia coli strain KY1436 as the host micro-organism, we established an efficient system for the production of human liver arginase protein. Chromatographies on CM-Sephadex G-150, DEAE-cellulose and Sephadex G-150, followed by preparative agar-gel electrophoresis, yielded 10 mg of apparently homogeneous enzyme protein from 1 g (wet wt.) of E. coli cells. E. coli-expressed human liver arginase had chemical, immunological and most catalytic properties indistinguishable from those of purified human erythrocyte arginase. However, E. coli-expressed arginase was a monomer of Mr 35,000, whereas the purified erythrocyte arginase was trimer of Mr 105,000. They differed also in pH- and temperature-stabilities. Gel-filtration experiments with these two purified arginases under various conditions, as well as with unfractionated human liver and erythrocyte cytosol preparations, indicated that the native form of human arginase should be of Mr 35,000, and that the trimeric appearance of human erythrocyte arginase after purification was an artifact of the purification procedures. It was thus concluded that, in Nature, the liver and erythrocyte arginases are identical proteins.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2241902      PMCID: PMC1131788          DOI: 10.1042/bj2700697

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  26 in total

1.  Modified reagents for determination of urea and ammonia.

Authors:  A L CHANEY; E P MARBACH
Journal:  Clin Chem       Date:  1962-04       Impact factor: 8.327

2.  Liver arginase. III. Properties of highly purified arginase.

Authors:  D M GREENBERG; A E BAGOT; O A ROHOLT
Journal:  Arch Biochem Biophys       Date:  1956-06       Impact factor: 4.013

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Purification and properties of human erythrocyte arginase.

Authors:  M Ikemoto; M Tabata; T Murachi; M Totani
Journal:  Ann Clin Biochem       Date:  1989-11       Impact factor: 2.057

5.  Arginase deficiency in a 12-year-old boy with mild impairment of intellectual function.

Authors:  J Bernar; R A Hanson; R Kern; B Phoenix; K N Shaw; S D Cederbaum
Journal:  J Pediatr       Date:  1986-03       Impact factor: 4.406

6.  Multicopy expression vectors carrying the lac repressor gene for regulated high-level expression of genes in Escherichia coli.

Authors:  M J Stark
Journal:  Gene       Date:  1987       Impact factor: 3.688

7.  Molecular forms of human-liver arginase.

Authors:  L Bascur; J Cabello; M Véliz; A González
Journal:  Biochim Biophys Acta       Date:  1966-10-17

8.  Plasmid vectors for the selection of promoters.

Authors:  J Brosius
Journal:  Gene       Date:  1984-02       Impact factor: 3.688

9.  Immunologic studies of arginase in tissues of normal human adult and arginase-deficient patients.

Authors:  E B Spector; S C Rice; S D Cederbaum
Journal:  Pediatr Res       Date:  1983-12       Impact factor: 3.756

10.  The use of operon fusions in studies of the heat-shock response: effects of altered sigma 32 on heat-shock promoter function in Escherichia coli.

Authors:  R Yano; M Imai; T Yura
Journal:  Mol Gen Genet       Date:  1987-04
View more
  13 in total

1.  Crystallization of an apo form of human arginase: using all the tools in the toolbox simultaneously.

Authors:  Janet Newman; Lesley Pearce; Charles A Lesburg; Corey Strickland; Thomas S Peat
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-12-23

2.  Arginine deprivation and tumour cell death: arginase and its inhibition.

Authors:  Denys N Wheatley; Ruth Philip; Elaine Campbell
Journal:  Mol Cell Biochem       Date:  2003-02       Impact factor: 3.396

3.  Inhibition of human arginase I by substrate and product analogues.

Authors:  Luigi Di Costanzo; Monica Ilies; Katherine J Thorn; David W Christianson
Journal:  Arch Biochem Biophys       Date:  2010-02-12       Impact factor: 4.013

4.  Molecular basis of phenotypic variation in patients with argininemia.

Authors:  T Uchino; S E Snyderman; M Lambert; I A Qureshi; S K Shapira; C Sansaricq; L M Smit; C Jakobs; I Matsuda
Journal:  Hum Genet       Date:  1995-09       Impact factor: 4.132

5.  Absence of erythrocyte arginase protein in Japanese patients with hyperargininemia.

Authors:  C Hayakawa; S Aono; H Keino; N Mizutani; K Watanabe; M Ikemoto; M Totani; T Murachi; S Kashiwamata
Journal:  Eur J Pediatr       Date:  1991-09       Impact factor: 3.183

6.  Three novel mutations in the liver-type arginase gene in three unrelated Japanese patients with argininemia.

Authors:  T Uchino; Y Haraguchi; J M Aparicio; N Mizutani; M Higashikawa; H Naitoh; M Mori; I Matsuda
Journal:  Am J Hum Genet       Date:  1992-12       Impact factor: 11.025

7.  Expression, purification and characterization of arginase from Helicobacter pylori in its apo form.

Authors:  Jinyong Zhang; Xiaoli Zhang; Chao Wu; Dongshui Lu; Gang Guo; Xuhu Mao; Ying Zhang; Da-Cheng Wang; Defeng Li; Quanming Zou
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

8.  Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC).

Authors:  Sam-Mui Tsui; Wai-Man Lam; Tin-Lun Lam; Hiu-Chi Chong; Pui-Kin So; Sui-Yi Kwok; Simon Arnold; Paul Ning-Man Cheng; Denys N Wheatley; Wai-Hung Lo; Yun-Chung Leung
Journal:  Cancer Cell Int       Date:  2009-04-17       Impact factor: 5.722

9.  Increase in Red Blood Cell-Nitric Oxide Synthase Dependent Nitric Oxide Production during Red Blood Cell Aging in Health and Disease: A Study on Age Dependent Changes of Rheologic and Enzymatic Properties in Red Blood Cells.

Authors:  Daniel Alexander Bizjak; Christian Brinkmann; Wilhelm Bloch; Marijke Grau
Journal:  PLoS One       Date:  2015-04-22       Impact factor: 3.240

10.  Arginine deprivation, growth inhibition and tumour cell death: 2. Enzymatic degradation of arginine in normal and malignant cell cultures.

Authors:  R Philip; E Campbell; D N Wheatley
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.